Full Press Release Details
THIS DOCUMENT IS IMPORTANT AND REQUIRES
YOUR IMMEDIATE ATTENTION
If you are in any doubt as to what action
you should take, you are recommended to seek your own financial advice from your stockbroker or other independent adviser authorized
under the Financial Services and Markets Act 2000 (as amended by the Financial Services and Markets Act 2012).
If you have recently sold or transferred
all of your shares in AKARI THERAPEUTICS, PLC, please forward this document, together with the accompanying documents, as soon
as possible either to the purchaser or transferee or to the person who arranged the sale or transfer so they can pass these documents
to the person who now holds the shares.
AKARI THERAPEUTICS, PLC
(Registered No. 05252842)
NOTICE TO SHAREHOLDERS REGARDING DELAY TO ANNUAL GENERAL MEETING
Dear Shareholders of Akari Therapeutics,
May 21, 2018, Akari Therapeutics, Plc, ("Akari") issued a press release announcing the delay in the filing
of its Annual Report on Form 20-F for the year ended December 31, 2017 (the "Form 20-F") with the Securities
and Exchange Commission (the "SEC"). Pending the finalization of the Form 20-F and the resolution of
certain technical issues, the Board of Directors delayed the convening of its 2018 annual general meeting (the "Annual
General Meeting") of the shareholders of Akari. The Board of Directors of Akari is now pleased to notify you that
on July 18, 2018, the Form 20-F was filed with the SEC and on August 6, 2018, Akari's UK Statutory Accounts for the
year ended December 31, 2017 (the "UK Statutory Accounts") were submitted to Companies House. A copy
of the UK Statutory Accounts is available on Akari's website. Akari plans on convening its Annual General Meeting for 2018
Board of Directors thanks you for your support and looks forward to welcoming you to our Annual General Meeting
By Order of the Board of Directors of
Akari Therapeutics, Plc,